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Background: Toxicology and Emergency medicine textbooks recommend measurement of acetylcholinesterase
(AChE) in all symptomatic cases of organophosphorus (OP) poisoning but laboratory facilities are limited in rural
Asia. The accuracy of point-of-care (POC) acetylcholinesterase testing has been demonstrated but it remains to be
shown whether results would be valued by clinicians. This study aims to assess the effect of seeing AChE POC test
results on the knowledge, attitudes and practices of doctors who frequently manage OP poisoning.
Methods: We surveyed 23 clinicians, who had different levels of exposure to seeing AChE levels in OP poisoned
patients, on a) knowledge of OP poisoning and biomarker interpretation, b) attitudes towards AChE in guiding
poison management, oxime therapy and discharge decisions, and c) practices of ordering AChE in poisoning
scenarios.
Results: An overall high proportion of doctors valued the test (68-89%). However, we paradoxically found that
doctors who were more experienced in seeing AChE results valued the test less. Lower proportions valued the test
in guidance of acute poisoning management (50%, p = 0.015) and guidance of oxime therapy (25%, p = 0.008), and
it was apparent it would not generally be used to facilitate early discharge. The highest proportion of respondents
valued it on admission (p < 0.001). A lack of correlation of test results with the clinical picture, and a perception
that the test was a waste of money when compared to clinical observation alone were also comments raised by
some of the respondents.
Greater experience with seeing AChE test results was associated with increased knowledge (p = 0.034). However, a
disproportionate lack of knowledge on interpretation of biomarkers and the pharmacology of oxime therapy (12-50%)
was noted, when compared with knowledge on the mechanism of OP poisoning and management (78-90%).
Conclusions: Our findings suggest an AChE POC test may not be valued by rural doctors. The practical use of AChE in
OP poisoning management is complex, and a poor understanding of how to interpret test results may have affected
its perceived utility. Future research should evaluate the impact of providing both AChE and training in interpretation
on clinicians’ attitudes and practice.
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Organophosphorus (OP) insecticide poisoning is respon-
sible for significant mortality and morbidity. The case-
fatality of OP self poisoning is high and there are over
200,000 annual deaths worldwide [1].
Toxicology and Emergency medicine textbooks recom-
mend that acetylcholinesterase (AChE) measurement
should be performed in all symptomatic cases of OP poi-
soning where the test is available, as this biomarker may
help confirm diagnosis and severity, guide the starting
and stopping of oximes by titrating the dose to changing
enzyme levels, and may help in guiding patient dispos-
ition [2-6]. Some text books recommend checking AChE
every 12-24 hours in symptomatic patients [3]. However,
accurate laboratory tests require complex collection
methods and a lack of availability of reliable point-of-
care (POC) laboratory services makes these recommenda-
tions difficult to follow [2]. Recent research has validated
the use of a POC acetylcholinesterase testing device (Test-
mate ChE) for acute OP self-poisoning in rural Sri Lanka,
but to date there are no studies to indicate how clinicians
would value, and use, such a test should it become avail-
able [7]. We were not able to find studies that evaluated
the benefit of POC devices in Asian countries, and a defi-
ciency in research surrounding the role of POC testing in
a rural hospital setting has also been identified by other
researchers [8].
We designed a study, which surveyed the knowledge,
attitudes and practices of clinicians in a secondary refer-
ral centre who are frequently treating OP poisoning. We
looked at what effect exposure to seeing AChE test re-
sults had on these parameters. We specifically asked
whether clinicians would order such a test if it were
available, and how useful it would be in their manage-
ment of OP poisoning (if at all). Our study intervention
was to make AChE results available to clinicians in acute
OP poisoning through POC testing, without specific
training or education on how to interpret the test
results.
Our hypothesis, based upon textbook recommenda-
tions, was that AChE tests would be widely ordered
and regarded as useful if they were made available.
We also hypothesised that doctors with greater experi-
ence of the test would report a higher perceived benefit
from the test in terms of showing improved knowledge
about OP poisoning, guidance of oxime therapy, and
the facilitation of early discharge of patients with mild
symptoms.
This study aimed to assess the knowledge, attitudes,
and practices amongst a range of treating clinicians who
manage high volumes of OP poisoned patient, and who
did not generally have access to AChE results. We also
aimed to report changes that occurred in relation to the
introduction of a point-of-care AChE device [7].Methods
The University of Peradeniya Ethical Review committee
approved the study, and consent was implied by partici-
pation in a paper survey.
Selection of doctors
The study targeted the practicing doctors who worked
in the General Medical ward and intensive care ward of
a secondary referral centre (with approximately 800 hos-
pital beds) in a rural Sri Lankan setting. All levels of the
medical hierarchy including Consultants, Senior House
officers (SHO’s), Medical officers (MO’s), and house offi-
cers (HO’s) were included in the study.
Intervention
The intervention consisted of the provision of AChE re-
sults from OP poisoned patients, over a 13 month period,
to treating clinicians. Clinicians were surveyed at begin-
ning and end in order to capture respondents with a
range of experience of the seeing AChE test results (see
Additional file 1: Figure S1).
Measurement of AChE results
Blood samples were taken from all consenting OP poi-
soned patients admitted to the medical wards and inten-
sive care unit by trained research assistants according to
a study protocol and the results were added to the pa-
tient record so that clinicians could use this information
if they desired.
The RBC-AChE and PChE levels were measured,
using the Test-mate ChE point-of-care device, before
and after doses of oxime in patients who were on this
therapy. These results were graphed to highlight any re-
lationship to doses given (see Figure 1), in a similar fash-
ion to what has been recommended in the literature [5].
AChE testing protocol
The test was made available in the hospital for 13
months during the time of the survey. A specific protocol
guided the frequency and timing of blood tests in relation
to oxime doses (see Additional file 2). Symptomatic pa-
tients who were treated with oximes had blood tests taken
pre and post doses of oxime during the first 48 hours, and
a pre and post dose test was taken on a daily basis there-
after. Symptomatic OP poisoned patients who weren’t
treated with oximes were tested at the same time points,
omitting the post oxime measurement.
Asymptomatic patients had an initial blood test fol-
lowed by a daily blood test thereafter. Patients with un-
known poisoning were treated as described depending
on whether they were symptomatic or not, and whether
they were being treated with oximes or not. After 5 days
of admission the frequency of blood testing was reduced
to alternate day testing.
Figure 1 Shows the method of making AChE levels from OP poisoned patients available to treating clinicians (study intervention). Red
blood cell acetylcholinesterase (AChE) and plasma cholinesterase (PChE) results were presented to clinicians via results sheet consisting of a table
and graph which was added to patient record.
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were performed
Internal medicine physicians were responsible for the
management of all pesticide poisoned patients who were
treated according to local practice. Symptomatic OP poi-
soned patients were generally resuscitated with atropine
via an intravenous bolus followed by infusion, with the
dose titrated to clinical response. Oximes were some-
times prescribed depending on the preference of the
treating physician.
Study endpoints
Survey of treating doctors
A self reported survey (Additional file 3) was distributed
to all the doctors including an information sheet ex-
plaining the confidentiality of the data that would be
obtained.
The survey had 3 components:-
1) 25 True/false statements (worth 1 mark each)
organized into 5 questions on knowledge of OP
poisoning, use of oximes and AChE testing
2) Short answer questions assessing attitudes towards
AChE testing and choice of oxime therapy
3) Scenario based questions assessing clinical practice
regarding ordering AChE tests, oxime therapy, and
patient discharge.
The principal investigator delivered the questionnaire
personally to each doctor in the sampling frame of 40
doctors responsible for treating poisoned patients. They
were instructed to complete and return the question-
naire as soon as possible.
True/false knowledge questions
The knowledge component comprised 5 areas each cov-
ered with 5 true/false statements. Each correct answer
was given one mark and each incorrect answer a nega-
tive mark resulting in a maximum score of 5 and a mini-
mum score of -5 for each of the 5 areas, which was then
converted into a percentage. The questions tested know-
ledge on the mechanism of OP pesticides toxicity, the
inhibition of AChE, types of biomarker in OP poisoning,
the clinical correlation of biomarker levels in poisoned
patients and the response of AChE to oximes (Additional
file 3 2.1). The level of difficulty was aimed at ‘expert’ level
(ie. a level that a toxicologist could be expected to know).
Short answer questions on experience and attitudes
A short answer question format was used to assess the
doctors’ prior experience with treating OP poisoned pa-
tients, number of AChE test results seen, and perceived
usefulness of the AChE test (Additional file 3 2.2). The
doctors usual practice regarding the dose and durationof oximes therapy in mild, moderate and severe OP poi-
soning was recorded in this section.
Scenario evaluation of attitudes and practice in cases of
OP poisoning
The last part of the survey consisted of four commonly
encountered patient scenarios: two scenarios with severe
poisoning, and florid cholinergic signs, and two scenar-
ios with mild poisoning, either receiving or not receiving
oximes (Additional file 3 2.3). These scenarios were
based upon commonly encountered patients. The sce-
narios assessed whether oximes would be prescribed,
and whether an AChE test would be ordered (and thus
considered beneficial OP poisoning management) at dif-
ferent time points in course of the patient admission.
Survey questions also explored the willingness to dis-
charge a mildly poisoned patient earlier than the stand-
ard 4 days of inpatient observation.
Clarifying statements as an adjunct to survey data
We provided respondents with the opportunity to clarify
their choices with free text. Headings such as “Com-
ments…”, or prompts like “Why/Why not?” would follow
questions that required either a binary or categorical an-
swer such as “Do you think an acetylcholinesterase level
(AChE) will be useful in helping guide treatment with ox-
imes?” (see Additional file 3 2.2 & 2.3 for examples of
survey).
Survey analysis
The study was initially designed to compare survey
responses before and after exposure to the interven-
tion (which was participation in an observational study
providing doctors with bedside AChE results). Because
some doctors reported prior experience with AChE tests,
and some respondents reported having no experience of
seeing AChE levels after the intervention we decided to
analyse the survey respondents as a cross sectional sam-
ple categorizing respondents according to level of ex-
perience with seeing AChE test results, and comparing
the groups. Respondents were divided into three groups
(no tests, 1-5 tests, or 5-20 tests) based on the number
of AChE test they reported they had seen, which was
asked in the first section of the survey. Three doctors
completed the survey twice during the study period and
we only used the first survey response in this group so
that the data we analysed was uniform with regards to
not having previously completed a survey (see Additional
file 1: Figure S1).
Statistical tests
The mean scores from the knowledge questions were
compared using the oneway ANOVA test. The categor-
ical answers to the survey questions were analysed using
Table 1 Survey respondent characteristics
Number of respondents (%)
Seniority
Consultant 3 (14%)
House officer 11 (50%)
Medical officer 5 (23%)
Senior House officer 3 (14%)
Specialty
Medicine 16 (72%)
Intensive Care 6 (27%)
No of OP poisoned patients seen
Less than 5 2 (9%)
5 to 20 5 (23%)
21 to 50 5 (23%)
51 to 100 5 (23%)
greater than 100 5 (23%)
Exposure to AChE tests
Zero 11 (50%)
1 to 5 7 (32%)
5 to 20 4 (18%)
21 to 50 0 (0%)
51 to 100 0 (0%)
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the Fisher’s exact test where the data was nominal. The
answers for some questions were coded as ordinal data
where some authors could have viewed it as nominal
data. For example, when respondents were asked if AChE
could guide oxime therapy and the possible answers were
“no”, “not sure” or “yes”, because in this context “not
sure” represented a point mid way between “yes” and
“no”. Also in the answers where respondents would select
the dose of oxime that would be prescribed, the categor-
ical choices were an increasing dose so we coded their
responses as an ordinal variable. The scenario data which
comprised multiple responses from doctors were ana-
lysed using generalized estimating equations (GEE). Asso-
ciations between patient risk factors and the decision to
order AChE test were expressed using odds ratios. All
statistical calculations were performed on STATA version
12, and graphs drawn on Prism version 6.
Results
The 22 doctors who were included in the analysis con-
sisted of both senior and junior medical staff from de-
partments of medicine (68%) and intensive care (32%),
and they reported treating on average 51-100 cases of
OP poisoning per year (see Table 1). Their experience of
seeing the point-of-care AChE test results ranged from
never having seen a test previously (ie ‘0 tests’) in 11
participants, to having seen ‘1-5 tests’ in 7 participants,
and ‘5-20 tests’ in 4 participants.
Knowledge
Those with most experience of AChE test results (eg. 5-
20 tests) had the highest knowledge with a significant in-
crease noted in the total score (p = 0.034, see Figure 2).
This was most marked in the questions to do with “bio-
markers of exposure”, “interpreting AChE in OP”, and
“oximes in OP poisoning”, but the increase only reached
statistical significance for question 5 on “oximes in OP
poisoning” (p = 0.046).
Attitudes: AChE in OP poisoning management
The perception that AChE test was useful in managing
OP poisoning was 100% amongst respondents with no
AChE test experience (0 tests) and minimal experience
(1-5 tests), but was significantly less (50%) in respon-
dents that had the most experience of seeing the most
test results (5-20 tests) (p = 0.035, Figure 3a, Table 2).
However, the two respondents who stated the test was
“not useful” qualified their answers with the following
statements suggesting a mixed impression about the util-
ity of the test;-
“Not necessary to manage OP poisoning but useful to
identify (diagnosis)”“AChE level is not related to the amount of poison or
the clinical symptoms but is useful in unknown poison
management”
The AChE test was noted to be helpful in guiding ox-
ime therapy in 73% and 86% of respondents with no ex-
perience, or minimal experience, but this proportion was
significantly less (25%) amongst respondents with the
most experience of seeing AChE test results (p = 0.05,
see Figure 3b, Table 2).
Respondents who reported that the test was helpful in
guiding oximes clarified their choice with comments
that valued the role of AChE in assessing severity of
poisoning, and the titration of AChE levels with oxime
administration;-
“I think acetylcholinesterase is a fairly reliable method
of assessing the level of poisoning”
“need to check whether the AChE level is up or down
with oxime”
Others raised concerns regarding the interpretation of
test result despite stating that they thought it was helpful;-
“Yes. But I am not sure of a cut off point to decide on
giving oxime - Evidence is needed on this”
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Figure 2 Knowledge scores for questions (based on answers to true/false statements). This column graph shows the differences in scores
by level of experience with the AChE test.
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oximes. I don’t think there is a symptomatic
correlation”
Conversely, respondents who did not believe that the
test was helpful in guiding oximes, expressed concern
about the clinical correlation of AChE in OP poisoning;
“(AChE) level does not correlate with clinical
symptoms of the patient”
as well as valuing clinical assessment over biomarker
evaluation;
“the most important thing is whether the patient is
symptomatic or not”
The oxime dose and duration in relation to severity of
poisoning, and the range of oxime prescription patterns
amongst survey respondents is shown in Table 2.
The majority (75%) of the group with most experience
chose a dosing regime of “2 g intravenous bolus followed
by 500 mg/hour intravenous infusion”, compared with 9%
and 0% of respondents from the subgroups with no ex-
perience and minimal experience (p = 0.008, see Figure 4a).These latter two subgroups chose to use a 1 g boluses
every 6 hours, 91% and 86% of the time, instead.
The subgroup with most experience also chose a “flex-
ible” duration of therapy contrasting those with no ex-
perience or minimal experience, who chose 48 hours of
therapy in 67% and 71% of responses respectively (p =
0.089, see Figure 4b).
The comments for this section clarified that the popular
“flexible” duration of therapy in the group of respondents
with most experience was related to clinical recovery, (see
examples below);-
“Until the patient is asymptomatic or off atropine”
“Until the patient gets rid of the OP effects clinically”
No respondents made specific reference to the concept
of an AChE level guiding either the “dose” or “duration” of
oxime therapy in the clarifying comments for this section.
Scenario analysis: ordering AChE at different time points
in admission
“Time” (since admission) was a factor affecting whether
respondents would order an AChE test, with a lower
propensity for ordering an AChE test each subsequent
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Figure 3 Attitudes towards AChE testing in organophosphorus
management. The perceived value of an AChE level (a) in the
treatment of organophosphorus poisoning, and (b) in the guidance
of oxime therapy is shown according to level of experience with
the test.
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0.001, see Figure 5). AChE was ordered most frequently
on admission (ranging from 86% to 65%, depending on
severity and concurrent oxime therapy), and a progres-
sive decline was noted during the following 3 days of
hospital admission. Conversely there was an increased
propensity for ordering an AChE test with greater sever-
ity of poisoning (OR 1.22 [1.10- 1.37], p < 0.001). There
was a trend for increased propensity of ordering an
AChE test in scenarios where oxime therapy was con-
current, however the influence of “oxime therapy” was
not statistically significant (OR 1.09 [0.96-1.25], p =
0.182). We noted a lower propensity for ordering
AChE in those with the most experience compared thosewith no test experience, a difference which approached
statistical significance (OR 0.78 [0.61-1.00], p = 0.052),
when level of experience with seeing AChE test was
considered.
Scenario analysis: ordering AChE and guidance of
oxime therapy
A minority of clarifying comments in this section of the
survey stated that ordering of AChE would help with
making a decision about oxime therapy;-
“to decide whether to prescribe pralidoxime or not”
[Severe poisoning, oximes, Day 2]
“can obtain a relative idea of the proportion of aging”
(no specific reference to oximes; but reference to ‘aging’
may be implied to relate to the effectiveness of oxime
therapy) [Severe poisoning, no oximes, Day 3]
however, such comments were not offered by the major-
ity or respondents, nor were they offered over the range
of time points in the scenario.
We noted a trend for higher proportions ordering an
AChE test after oximes were stopped, in the scenario of
severe poisoning, when comparing respondents with
minimal and most experience (100% and 75% respect-
ively), with those with no experience (37%, see Additional
file 4: Figure S2). This observation suggests the use of
AChE in guiding a decision to re-starting oximes, how-
ever, the difference in proportions was non significant (p
= 0.450). Furthermore, the clarifying comments did not
clearly identify this as a reason for AChE being ordered at
this time point in any of the respondents, regardless of
their level of experience.
One comment indicated that AChE may be used in
this way by saying the reason for ordering the test post
stopping oximes was;
“to compare with initial enzymes”
but there was a lack of detail about what action would
be taken if the AChE enzyme levels had decreased, and
it is uncertain whether the respondent would use the
comparison to restart oxime therapy.
Scenario analysis: early discharge and ordering AChE
If AChE was perceived as helpful in facilitating early dis-
charge one would expect a high proportion of respon-
dents ordering an AChE test on day 2 or day 3 in the
scenarios of a mildly poisoned OP patient, and com-
ments that showed a link between the use of an AChE
level to aid the decision to discharge a patient.
This was not the case as respondents suggested they
would order an AChE test on only 38% of occasions
Table 2 Attitudes towards oxime therapy and AChE testing †
Question Response Level of AChE experience p value
"0 tests"
n (%)
"1-5 tests" (%) "5-20 tests"
n (%)
What dose of intravenous pralidoxime would you prescribe
to a severely symptomatic patient?
None 0 (0%) 1 (14%) 0 (0%) 0.008
1 g 6 hourly 10 (91%) 6 (86%) 1 (25%)
2 g bolus + 500 mg
continuous IV infusion
1 (9%) 0 (0%) 3 (75%)
For what duration would you give the above dose? None 0 (0%) 1 (14%) 0 (0%) 0.089
24 hours 1 (11%) 0 (0%) 0 (0%)
48 hours 6 (67%) 5 (71%) 0 (0%)
Other time period 2 (22%) 1 (14%) 3 (100%)
What dose of intravenous pralidoxime would you prescribe
to a mildly symptomatic patient?
None 1 (9%) 4 (57) 1 (25%) 0.105
1 g 6 hourly 10 (91%) 3 (43) 2 (50%)
2 g bolus + 500 mg
continuous IV infusion
0 (0%) 0 (0%) 1 (25%)
For what duration would you give the above dose? None 1 (11%) 4 (57%) 1 (33%) 0.116
24 hours 0 (0%) 0 (0%) 1 (33%)
48 hours 7 (78%) 3 (43%) 1 (33%)
Other time period 1 (1%) 0 (0%) 0 (0%)
What dose of intravenous pralidoxime would you prescribe
to an asymptomatic patient who is not getting atropine?
None 6 (64%) 7 (100%) 4 (100%) 0.097
1 g 6 hourly 4 (36%) 0 (0%) 0 (0%)
2 g bolus + 500 mg
continuous infusion
0 (0%) 0 (0%) 0 (0%)
For what duration would you give the above dose? None 5 (56%) 4 (100%) 4 (100%) 0.435
24 hours 2 (22%) 0 (0%) 0 (0%)
48 hours 2 (22%) 0 (0%) 0 (0%)
Other time period 0 (0%) 0 (0%) 0 (0%)
Do you think an acetylcholinesterase level (AChE) will be
helpful in guiding treatment with oximes?
Yes 8 (73%) 6 (86%) 1 (25%) 0.051
Not sure 3 (27%) 1 (14%) 1 (25%)
No 0 (0%) 0 (0%) 2 (50%)
Is this test was available and affordable. Would it be useful
in treating OP poisoning?
Yes 9 (100%) 6 (100%) 2 (50%) 0.035
No 0 (0%) 0 (0%) 2 (50%)
† The total number of answers for each question do not always add up to 22 as some respondents omitted answering questions.
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home, and there was no association between the deci-
sion to order an AChE test and the decision to dis-
charge (see Figure 6). We also noted that in general a
low proportion (50%) of respondents would opt to dis-
charge a mildly symptomatic patient home on either
day 2 or day 3 post admission.
However, two respondents made the following clarify-
ing comments as reasons for ordering an AChE test;
“can discharge the patient early”
“it would decide in keeping or discharging the
patient”which suggests that the role of AChE levels in guiding
disposition decisions was considered by at least a minor-
ity of respondents.
Other reasons for ordering AChE based on comments
Respondents qualified their answers with clarifying com-
ments for just under half (48%) of the scenario questions
in favor of the decision to order an AChE test, with 48%
(see Additional file 5: Figure S3), providing some insight
into the thinking behind ordering and not ordering an
AChE test.
Many answers supported perceived value of AChE
testing having a role in diagnosis of OP poisoning, and
gauging severity;
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Figure 4 Attitudes towards oxime dose (a) and duration (b) in a case of severe OP poisoning, show by level of AChE test experience.
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http://www.biomedcentral.com/1472-6963/14/104“(useful) in cases of unknown pesticide poisoning for
guiding treatment on certain occasions”
“I think acetylcholinesterase is a reliable method of
assessing level of poisoning”
“it will be an indicator showing the degree of poisoning”
and in guiding oxime therapy;
“Titrate the pralidoxime dose frequency with the
enzyme level in the plasma”“when to start oximes, When to stop oximes”
“(with measurement of AChE) unnecessary treatment
can be avoided”
However, the details of specifically how oxime doses
would be titrated were absent as highlighted in the pre-
vious section.
Many statements that were against the use of AChE
in management of OP poisoning highlighted the senti-
ment that “clinical assessment” should take precedence
over biochemical guidance;
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Figure 5 Practice; showing proportions of respondents who would order an AChE test in different clinical scenarios. The effect of time,
clinical severity, and concurrent oxime therapy on willingness to order an AChE test is demonstrated.
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patient”
“Most important thing is if the patient is symptomatic
or not”
and other comments raised concerns about the potential
wastefulness of such an investigation;
“this will not change patient management, it will
waste money”
Discussion
The literature states that the AChE levels can help guide
OP poisoning management, oxime therapy and dispos-
ition decisions, and our study found that “overall” a high
proportion of surveyed doctors valued ordering AChE
test in accordance with these recommendations. How-
ever, paradoxically we noted that doctors with more
experience of seeing test results through the study inter-
vention were less likely to value the AChE test in guid-
ing OP poisoning management and oxime therapy, and
there was no suggestion it would be used to facilitate
early discharge. Respondents raised a number of general
concerns about a lack of correlation between test results
and the clinical picture, and a perception that ordering a
test would be a waste of money when compared to the
standard practice of clinical observation.The experience of seeing test results was associated
with improved knowledge scores across all domains.
These scores were highest for knowledge in clinical
management of OP poisoning (78% improving to 90%
post intervention), contrasting the lower scores for ques-
tions related to biomarkers and the use of oximes (12-
20% improving to 40-50% post intervention). A relative
lack of knowledge about the interpretation of biomarkers
in guiding general management and oxime therapy may
have been one factor explaining our unexpected findings.
Difficulty in interpretation of results: Pitfalls in
AChE monitoring
AChE is being increasingly recognized as a complex test
with regard to the interpretation of levels in the context of
acute OP poisoning. Difficulty with interpretation of AChE
levels arises for several reasons including a variation in
cholinesterase inhibition from different types of OP agents
[9], the wide normal range for both kinds of AChE (plasma
cholinesterase and red cell cholinesterase), irreversible in-
hibition (“ageing”) by a proportion of the enzyme, and the
fact that inhibition can be non specific due to other factors
that can reduce AChE levels such as concurrent chloro-
quine therapy, or conditions like pernicious anaemia [1,3].
Re-inhibition of AChE may occur when an oxime is dis-
continued and there is a residual poison load. Thus, in such
situations it may be dangerous to discharge based on early
recovery of AChE. Our study found that doctors generally
Total=17
8
7
1
1a)
Day 2
Total=16
6
9
1
b)
Total=18
8
5
1
4
Day 3
Total=17
5
5
3
4
Discharged /
AChE
ordered
Discharged /
AChE not
ordered
Not Discharged /
AChE ordered
Not Discharged /
AChE not
ordered
Figure 6 Association of ordering an AChE test with the early discharge of a mildly poisoned patient who has a) initially received
oximes, or b) initially not received oximes.
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ever, the explanations provided suggested that such nu-
anced considerations were not relevant. Further, comments
suggested clinicians found it challenging to negotiate the
pitfalls in AChE measurement highlighted in textbooks.
Lack of specific decision rules for AChE guidance
The lack of knowledge regarding AChE interpretation
may in part be explained by a lack of precise values of
AChE informing decisions rules in OP poisoning manage-
ment [2-6]. This gap in the literature was apparent on fur-
ther examination of recommendations regarding the use
of AChE in guiding oxime therapy and dispositiondecisions in particular. In relation to re-starting oximes,
for example, one text quoted “further deterioration of cho-
linesterase activity should be treated by reinstituting a pra-
lidoxime infusion, even though the patient may still be
asymptomatic” [3], without providing numeric qualifica-
tion on the ‘degree of inhibition’ that should lead to ac-
tion. The challenge of interpretation of such advice, and a
similar style of advice in other textbooks was well de-
scribed in the comments of one respondent in particular
from the scenario section of the survey who wrote;
“I am not sure of a cut off point to decide on giving
oxime - Evidence is needed on this”.
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practical use of AChE in guiding oxime therapy. While
some texts have suggested graphical representations of
the titration of oximes with AChE levels [7], these only
provide guidance on principles of antidote titration ra-
ther than specific levels that can be referenced in an al-
gorithmic fashion. More sophisticated laboratory test
methods exist to support decision making and oxime
therapy; for example the in vitro measurement of re-
sponse to oximes and estimation of the reactivatable
RBC-AChE enzyme [10,11]. However, the practical em-
ployment of these methods in POC tests has not yet
been described or validated.
There is also little data to guide interpretation of
AChE for it’s role in of supporting disposition decisions.
Here many texts recommend discharge in association
with other features like cessation of a need for further
antidote therapy, clinical improvement and “stable” or
“minimally depressed” cholinesterase activity [2,3].
Clinical correlation of AChE, and outcome
On the other hand, the evidence on how RBC-AChE can
provide guidance about diagnosis and severity of poison-
ing has been more clearly described, with extent of in-
hibition correlated with clinical findings [7,10,12-16].
However, even the when specific ranges of AChE are
known, the application of this information in a clinical
setting may be complex, as it requires clinicians to in-
corporate an understanding of the potential pitfalls that
can be encountered. Variations in AChE inhibition from
different agents may lead to “some patients presenting
highly symptomatic after minimal reduction in cholin-
esterase, whilst others can be asymptomatic after losing
50% of activity” [3].
Thus AChE appears to be a test where background
factors, such as understanding it’s role in pathophysi-
ology of poisoning, are important in making decisions
about treatment, but there is no specific guidance avail-
able for doctors.
This point can be illustrated by contrasting the use of
AChE in OP poisoning management with the use of peak
expiratory flow rate (PEFR) in management of acute
asthma. PEFR can also be used for guiding diagnosis, se-
verity and disposition decisions in emergency depart-
ments. The difference is that published decision rules
for the use of PEFR in asthma management exists
[17,18], whilst similar decision rule research and evi-
dence based guidelines for the use of AChE in OP poi-
soning management is lacking.
Study intervention provided without education or training
No attempt was made to train doctors on how to use
the test, the results were presented in a format that
would allow the AChE test to show benefit, such as bygraphing pre and post oxime doses (see Figure 1) to facili-
tate guidance of oxime therapy. Given national recom-
mendations [4] were available for AChE interpretation we
expected the test to be used widely in clinical treatment.
Our results highlight the effects of introducing a complex
test without specific training in how to interpret test
results.
It is interesting that knowledge increased without di-
dactic teaching. One possible explanation is that by see-
ing the tests results doctors had an increased awareness
about the mechanisms of OP poisoning (inhibition of
the AChE enzyme), and the use of oximes to regenerate
inhibited AChE.
A qualitative study assessing the introduction of a dif-
ferent POC test reported that some clinicians were more
likely to use certain tests if they had recent formal edu-
cation in the domains surrounding the test [8]. The diffi-
culties surrounding the interpretation of AChE in the
context of OP poisoning, that have been observed in the
current study, emphasise the importance of training doc-
tors who may use the test on the assay’s capabilities and
limitations. Such training should include appreciation of
the pitfalls of collection, measurement, interpretation of
AChE results in the context of guiding oxime therapy
and facilitating discharge.
Educational interventions are likely to affect attitudes
and practices, and future studies should therefore in-
corporate concurrent education into the assessment of
new POC tests.
Limitations
Our initial planned design was pre-post analysis but be-
cause of the high turnover of doctors in the study inter-
vention wards, we ended up with data suited to a cross
sectional survey, comparing subgroups by “level of ex-
perience with seeing AChE test results”. Small numbers
in these sub groups, despite a fairly good response (26
out of 40) was a limitation. However, the effect of the
study intervention was large enough to result in signifi-
cant differences between subgroups in some domains.
Less “AChE test experience” than expected
Whilst we recorded a range of AChE experience amongst
survey respondents we expected the range to be broader,
with some doctors potentially seeing up to 100 test results
(20 tests was the highest reported experience in our
study). A total of 81 patients had AChE levels measured
during the study intervention and many of these patients
had multiple tests. Some respondents may have inter-
preted “tests seen” as the number of patients with tests
seen. More objective data on exposure to tests, or more
detail on reported exposure (eg. asking both how many
patients with results and how many tests) may have pro-
vided a more accurate classification of level of experience.
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be due to the high staff turnover.Mixed methods approach for future research on use of
POC tests
We used a quantitative study design to assess know-
ledge, attitudes and practices, however, the collection of
comments that respondents sometimes used to qualify
their survey choices provided a deeper understanding of
the main study results. The quantitative answers consid-
ered in isolation may have given a different impression.
For example, whilst we found that increased experience
with AChE tests led to decreased value being attributed
to the test, often the same respondents who said they
would not order a test also provided nuanced comments
about its potential benefits. This highlights the degree of
ambiguity amongst experienced respondents in their at-
titudes towards the test.
However, only 53% of questions had an associated
comment, and thus it is possible that certain comments
may preferentially highlight the views of a few individ-
uals. We also observed that respondents who answered
in favour of the test more frequently qualified their an-
swer with a comment (67%) than when they chose not
to order the test (43%), see Additional file 5: Fgure S3
Blattner et al. assessed the acceptability and effective-
ness of POC testing in rural New Zealand, and carried
out both a quantitative study, and a qualitative thematic
analysis [8,19]. Their quantitative study demonstrated
the cost effectiveness of introducing the test through
ability to avoid unnecessary transfers, as well as facilitate
discharge. However, the qualitative component of their
research uncovered some of the challenges of introdu-
cing POC testing, such as increased workload, and the
challenge of continued professional education given that
“up-skilling” of doctors may be required for the inter-
pretation of some of the available test results. These au-
thors also commented that their depth of understanding
about the impact of introducing the test would have
been missed if they had relied on the quantitative results
alone.
We suggest that future research on POC tests use a
mixed methods approach with the development of a ro-
bust study design for its qualitative component.Conclusions
An AChE POC test was valued by a majority of rural
doctors but it was valued less by those with greater ex-
perience of seeing test results. These unexpected find-
ings could be related to the complex nature of the test,
no decision rules and poor knowledge of the interpret-
ation. The absence of specific education on how to inter-
pret test results may have been a contributing factor.We recommend that health services that want to
introduce a POC AChE test provide doctors with con-
current training on how to use and interpret AChE re-
sults, and research the impact through a mixed methods
approach. Such research should ideally be conducted
with larger numbers, and include medical staff with a
wide range of experience and include multiple primary
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